Integrity,Innovation,Reliability,Responsibility
Media and Public Relations
media@hinovapharma.com
- Hinova Pharmaceuticals receives FDA Fast Track Designation for HP518 for Treatment of AR+ Triple-Negative Breast Cancer (TNBC) 2024.07.05
- Hinova's Investigational New Drug (IND) Application of FAK inhibitor HP530S Tablets was Accepted by NMPA 2023.02.10
- Hinova's Clinical Trial Application for the Combination of HP501 Sustained-release Tablets and xanthine oxidase inhibitors in the Treatment of Hyperuricemia/Gout was Accepted by NMPA 2023.02.06
- Hinova Receives FDA Proceed Authorization for its IND Application for HP518, an Orally Bioavailable Chimeric Degrader Targeting Androgen Receptor for Prostate Cancer Treatment 2023.02.01
- Hinova Disclosed the Preclinical Results of HP518 (Oral AR PROTAC) at the 5th Annual TPD Summit 2022.10.28
- Hinova Announces Phase III Clinical Trial of Deutenzalutamide (HC-1119) in Chinese Patients with castration-resistant prostate cancer (mCRPC) Met Primary Endpoint 2022.06.27
- Hinova Today Listed on the Science and Technology Innovation Board (the “STAR Market”) of the Shanghai Stock Exchange (SSE) in China, Relying on PROTAC and Deuterium Technology to Develop Innovative D 2022.04.12
- Hinova Announces First Patient Dosed in a Phase I Clinical Trial of HP518, an Orally Bioavailable Chimeric Degrader Targeting Androgen Receptor for Prostate Cancer Treatment 2022.01.20
- Hinova's Clinical Trial Application of HP558 for the Treatment of gastrointestinal Tumors was Accepted by NMPA 2021.09.14
- Hinova Completes Series C Financing of Nearly RMB 1 Billion to Accelerate Clinical Trials and Global Development 2020.09.30
- Hinova Self-developed Prostate Cancer Drug HC-1119 Enters Global Multicentered Phase III clinical trial 2019.08.01
Postal Code: 610041
Headquarters address: No. 2 and No. 3, Floor 4, Building 1, Rongyao Building, Keyuan South Road 5, High-tech Zone, Chengdu City, Sichuan Province
TOP
关注公众号
